Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 3
2005 6
2006 5
2007 1
2008 2
2009 3
2010 4
2011 4
2012 8
2013 7
2014 6
2015 4
2016 11
2017 10
2018 3
2019 2
2020 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, Nimubona S, Goasguen J, Wattel E, Zini G, Torregrosa Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Navarro R, Patriarca A, Stamatoullas A, Götze K, Puttrich M, Mossuto S, Solary E, Gloaguen S, Chevret S, Chermat F, Platzbecker U, Fenaux P. Itzykson R, et al. Among authors: wattel e. J Clin Oncol. 2023 Apr 1;41(10):1888-1897. doi: 10.1200/JCO.22.00437. Epub 2022 Dec 1. J Clin Oncol. 2023. PMID: 36455187 Clinical Trial.
How mRNA is misspliced in acute myelogenous leukemia (AML)?
Mohamed AM, Thénoz M, Solly F, Balsat M, Mortreux F, Wattel E. Mohamed AM, et al. Among authors: wattel e. Oncotarget. 2014 Oct 30;5(20):9534-45. doi: 10.18632/oncotarget.2304. Oncotarget. 2014. PMID: 25375204 Free PMC article. Review.
Potential Role of OCT4 in Leukemogenesis.
Picot T, Kesr S, Wu Y, Aanei CM, Flandrin-Gresta P, Tondeur S, Tavernier E, Wattel E, Guyotat D, Campos L. Picot T, et al. Among authors: wattel e. Stem Cells Dev. 2017 Nov 15;26(22):1637-1647. doi: 10.1089/scd.2017.0134. Epub 2017 Oct 16. Stem Cells Dev. 2017. PMID: 28911263
Cell dynamics and immune response to BLV infection: a unifying model.
Florins A, Gillet N, Asquith B, Boxus M, Burteau C, Twizere JC, Urbain P, Vandermeers F, Debacq C, Sanchez-Alcaraz MT, Schwartz-Cornil I, Kerkhofs P, Jean G, Théwis A, Hay J, Mortreux F, Wattel E, Reichert M, Burny A, Kettmann R, Bangham C, Willems L. Florins A, et al. Among authors: wattel e. Front Biosci. 2007 Jan 1;12:1520-31. doi: 10.2741/2165. Front Biosci. 2007. PMID: 17127399 Free article. Review.
Inactivation of hTERT transcription by Tax.
Gabet AS, Mortreux F, Charneau P, Riou P, Duc-Dodon M, Wu Y, Jeang KT, Wattel E. Gabet AS, et al. Among authors: wattel e. Oncogene. 2003 Jun 12;22(24):3734-41. doi: 10.1038/sj.onc.1206468. Oncogene. 2003. PMID: 12802280
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Adès L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Dimicoli-Salazar S, Braun T, Beyne-Rauzy O, Marolleau JP, Cheze S, Park S, Cluzeau T, Nimubona S, Bordessoule D, Benramdane R, Quesnel B, Amé S, de Botton S, Chermat F, Preudhomme C, Chevret S, Fenaux P. Adès L, et al. Among authors: wattel e. Br J Haematol. 2022 Aug;198(3):535-544. doi: 10.1111/bjh.18193. Epub 2022 Apr 19. Br J Haematol. 2022. PMID: 35438802 Clinical Trial.
73 results